Price T Rowe Associates Inc Ascendis Pharma A/S Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,875,491 shares of ASND stock, worth $367 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,875,491
Previous 2,256,102
16.87%
Holding current value
$367 Million
Previous $352 Million
7.94%
% of portfolio
0.04%
Previous 0.04%
Shares
19 transactions
Others Institutions Holding ASND
# of Institutions
275Shares Held
60MCall Options Held
217KPut Options Held
73.3K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.01 Billion38.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.07 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.98MShares$975 Million15.67% of portfolio
-
Janus Henderson Group PLC London, X04.43MShares$867 Million0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$833 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $10.9B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...